可切除非小细胞肺癌接受新辅助免疫治疗联合化疗后18F-FDG PET/CT代谢参数的预后价值
该回顾性研究分析了131例经病理确诊、接受3个周期新辅助免疫治疗联合化疗后可切除的非小细胞肺癌患者,比较基于iRECIST的CT评估与基于PERCIST的PET/CT评估,并评估治疗前后PET代谢参数的预后价值。结果显示PERCIST与预后一致性高而iRECIST一致性低,两者差异有统计学意义(P<0.001),ΔSUVmax是最具预测价值的参数。
要点
- PERCIST评估与预后一致性高,iRECIST一致性低,两者差异有统计学意义(P<0.001)。
- 治疗后PET代谢参数及治疗前后变化率(Δ)在ROC分析中均有显著差异(P<0.05)。
- 除ΔMTV(P=0.311)外,低风险组各参数生存均显著更高,ΔSUVmax最具预测价值。
核心结论
- 在可切除非小细胞肺癌新辅助免疫治疗联合化疗的预后评估中,PERCIST比iRECIST更准确,PET代谢参数尤其是ΔSUVmax能有效预测预后并支持临床决策。
研究设计与样本
- 回顾性分析131例经病理确诊、接受3个周期新辅助免疫治疗联合化疗后判定为可切除的非小细胞肺癌患者的临床数据。
- 评估治疗前和治疗后的PET代谢参数,比较基于iRECIST的CT评估与基于PERCIST的PET/CT评估。
- 采用ROC曲线分析及Kaplan-Meier生存分析(含单因素和Cox多因素分析)评估治疗后PET代谢参数的预后价值。
主要发现
- 基于PERCIST的PET/CT评估与预后一致性高,而基于iRECIST的CT评估一致性低,两种标准间差异有统计学意义(P<0.001)。
- ROC曲线分析显示治疗后PET代谢参数(postSUVmax、postSUVmean、postSUVpeak、postMTV、postTLG)及治疗前后代谢参数变化率(ΔSUVmax、ΔSUVmean、ΔSUVpeak、ΔMTV、ΔTLG)均有显著差异(P<0.05)。
- 单因素分析显示除ΔMTV(P=0.311)外,所有参数低风险组生存均显著更高;Cox多因素分析确定ΔSUVmax最具预测价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study investigates the predictive value of 18 F-FDG PET/CT metabolic parameters in patients with non-small cell lung cancer (NSCLC) undergoing neoadjuvant immunotherapy plus chemotherapy. METHODS: We conducted a retrospective analysis of clinical data from 131 patients with pathologically confirmed NSCLC who were deemed resectable after 3 cycles of neoadjuvant immunotherapy plus chemotherapy. Pretreatment and post-treatment PET metabolic parameters were evaluated. CT assessments based on immune response evaluation criteria in solid tumors (iRECIST) were compared with PET/CT assessments using the response criteria in solid tumors (PERCIST). ROC curve analysis and Kaplan-Meier survival analysis, including univariate and Cox multivariate analyses, were employed to assess the prognostic value of PET metabolic parameters after treatment. RESULTS: The PET/CT assessment based on PERCIST showed high consistency with prognosis, while the CT assessment based on iRECIST demonstrated low consistency. Statistically significant differences were observed between the iRECIST and PERCIST criteria ( P <0.001). ROC curve analysis revealed significant differences in post-treatment PET metabolic parameters (postSUVmax, postSUVmean, postSUVpeak, postMTV, and postTLG) as well as the percentage changes in metabolic parameters before and after treatment(Δ) (ΔSUVmax, ΔSUVmean, ΔSUVpeak, ΔMTV, and ΔTLG) ( P <0.05). Optimal cutoff values enabled stratification into high-risk and low-risk groups. Univariate analysis showed significantly higher survival in the low-risk group for all parameters except ΔMTV ( P =0.311), while Cox multivariate analysis identified ΔSUVmax as the most predictive. CONCLUSIONS: The PERCIST is more accurate than iRECIST in evaluating prognosis for NSCLC neoadjuvant immunotherapy plus chemotherapy. PET metabolic parameters, particularly ΔSUVmax, effectively predict prognosis and support clinical decision-making.
引用
- Cheng Y, Jiang ZP, Chen XB, et al. Prognostic Value of 18 F-FDG PET/CT Metabolic Parameters in Resectable Non-small Cell Lung Cancer Treated With Neoadjuvant Immunotherapy Plus Chemotherapy. Clin Nucl Med. 2025. PMID: 40108723. doi:10.1097/RLU.0000000000005863
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。